Category - Developments

Developments

Axxess acquires Complia Health

Axxess, a home healthcare technology provider, acquired Complia Health in move that adds more clients, more talent and even greater engagement with leading care providers among the Axxess family. Complia’s roster of...

July 24, 2023

Developments

Advent nabs rare pediatric disease designation for bronchopulmonary dysplasia in preemies

Advent Therapeutics received FDA rare pediatric disease designation for its vitamin A metabolic and reparative respiratory drugs for the prevention of bronchopulmonary dysplasia (BPD) in premature infants. BPD is a rare...

July 20, 2023

Developments

Eliem Therapeutics to explore strategic alternatives

Eliem Therapeutics (NASDAQ:ELYM) completed a review of its business, including the status of its programs, resources, and capabilities, and has decided to halt further development of its Kv7 program and to conduct a...

July 20, 2023

Developments

MindBio pre-screening patients in take-home LSD-microdosing Phase 2 study

MindBio Therapeutics Corp (CSE:MBIO; Frankfurt:WF6) started pre-screening for participant entry into Phase 2 LSD-microdosing clinical trials. The clinical trials are a world first with approvals for take home use of...

July 19, 2023

Developments

Neurogene and Neoleukin in merger accord

Close-held Neurogene and Neoleukin Therapeutics (NASDAQ:NLTX) entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Neurogene’s...

July 18, 2023

Developments

Anixa Biosciences breast cancer vaccine featured in Daily Mail article

A Phase 1 trial of Anixa Biosciences’ (NASDAQ:ANIX) breast cancer vaccine and women survivors were featured in an article on the website of England’s Daily Mail newspaper. Anixa’s CEO, Amit Kumar, Ph.D., described the...

July 17, 2023

Developments

Ondine receives TAYYABA HASAN IMPACT AWARD at IPA World Congress

Ondine Biomedical (LON:OBI) was awarded the TAYYABA HASAN IMPACT AWARD at the 18th World Congress of International Photodynamic Association (IPA) in Finland for demonstrating “exceptional perseverance and clinical...

July 17, 2023

Developments

Athira presents biomarker data in Alzheimer’s

Athira Pharma (NASDAQ:ATHA) is presenting new data supporting its pipeline of small molecule therapeutic candidates designed to enhance the HGF/MET neurotrophic system at the Alzheimer’s Association International...

July 17, 2023

Developments

First Wave BioPharma unlikely to hit primary endpoint in CF

First Wave BioPharma’s (NASDAQ:FWBI) is unlikely to achieve the primary endpoint based on preliminary results from the Phase 2 SPAN study for the treatment of exocrine pancreatic insufficiency in patients with cystic...

July 13, 2023

Developments

FDA clears Tryp’s IND for Phase 2a IBS study at MGH

The FDA completed a review of Tryp Therapeutics’ (CSE:TRYP; OTCQB:TRYPF) investigational new drug application, permitting the company to proceed with a Phase 2a clinical trial at Massachusetts General Hospital (MGH)...

July 13, 2023

Category - Developments

General

More